Former Kansas City Chiefs Placekicker spoke with Fox Business, CBS Sports, NBC and i24 News.
SAN DIEGO, Sept. 29, 2017 — Medical Marijuana, Inc. (OTC:MJNA), the first publicly traded cannabis company in the United States, today announced that portfolio company KannaLife Sciences‘ new spokesman Nick Lowery and former Kansas City Chiefs placekicker, generated a massive amount of media coverage across the United States about the dangers of chronic traumatic encephalopathy (CTE).
CTE is a degenerative neurological disease caused by repeated head trauma and only diagnosable with certainty in post-mortem examinations and can lead to symptoms like violent mood swings, depression and other cognitive difficulties. Because there is not much known about this debilitating disease, treatment and prevention options are bleak.
A September 26, 2017 interview with Fox Business’ Varney & Co., discussed current research on the diagnosis and treatment of CTE, and its relationship to professional sports organizations such as the NFL. Lowery also interviewed with CBS show Tiki and Tierney, where he discussed the applications of CTE prevention to other cases outside of the NFL, such as patients involved in traumatic car accidents. This was an interview that host Tierney described as “one of the most important interviews we’ve had on the show.”
“It’s encouraging to see the widespread national discussion about CTE research and treatment. We are always proud to be at the forefront of groundbreaking news that has the capacity to positively impact the world. A goal of our company has been to provide an alternative health-and-wellness awareness to the largest audience possible,” said CEO of Medical Marijuana, Inc. Dr. Stuart Titus. “We are thrilled to have Nick Lowery on board as spokesperson for Kannalife Sciences. Nick brings real world experience to our CTE efforts as well as incredible passion to find a solution for many ex-athletes who are suffering in the later stages of life.”
Additionally, Nick discussed the topic of CTE with these other media outlets:
About KannaLife Sciences
Kannalife Sciences, Inc. is a bio-pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. Kannalife Sciences currently holds an exclusive license with National Institutes of Health – Office of Technology Transfer (“NIH-OTT”) for the Commercialization of U.S. Patent #6630507, “Cannabinoids as Antioxidants and Neuroprotectants“ (the “‘507 Patent”). Kannalife is currently conducting research and development at the Bucks CountyPennsylvania Biotechnology Center in Doylestown, PA, for a target drug candidate to treat Hepatic Encephalopathy (HE) and Chronic Traumatic Encephalopathy (CTE). HE and CTE are both oxidative stress related diseases that affects the cognitive and behavioral functions, and the wellness of the brain.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.’s video statement, click here. Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties. The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.
Public Relations Contact:
Chief Executive Officer